What is the recommended inpatient management for an 84‑year‑old male with chronic heart failure, chronic kidney disease, diabetes, and a ventricular pacemaker who presents with acute decompensated heart failure, worsening renal function (eGFR low), elevated N‑terminal pro‑brain natriuretic peptide (NT‑proBNP), elevated troponin, and a large right pleural effusion?

Inpatient Management of Acute Decompensated Heart Failure with Cardiorenal Syndrome

This 84-year-old patient requires immediate aggressive intravenous loop diuretic therapy to achieve complete decongestion, with careful daily monitoring of renal function and electrolytes, while maintaining evidence-based heart failure medications unless hemodynamically unstable. 1, 2

Immediate Priorities

1. Aggressive Diuresis for Decongestion

The cornerstone of management is intravenous loop diuretics to address the severe volume overload evidenced by the large pleural effusion, pulmonary edema, and markedly elevated NT-proBNP (20,883 pg/mL). 1, 2, 1

Dosing strategy:

• Since this patient is likely on chronic oral diuretics (given chronic HF), start with intravenous furosemide at a dose at least equivalent to or higher than the home oral dose 1
• If inadequate response to bolus dosing (>240 mg/day), consider:
  • Continuous intravenous furosemide infusion (Class IIa, Level B) 3
  • Addition of thiazide diuretic (metolazone or hydrochlorothiazide) for synergistic effect (Class IIa, Level B) 3

Critical monitoring (Class I, Level C): 1, 2

• Daily assessment of symptoms, weight, urine output
• Daily measurement of BUN, creatinine, and electrolytes (potassium, sodium)
• Volume status examination (jugular venous pressure, lung sounds, peripheral edema)

2. Management of Worsening Renal Function (Cardiorenal Syndrome)

The acute rise in creatinine (1.4→1.83) and BUN (20→40) with declining eGFR (50→36) represents cardiorenal syndrome type 1. This is common and does not automatically mandate stopping diuretics or RAAS inhibitors. 3, 4, 5

Key principle: In the context of severe congestion, transient creatinine increases during aggressive diuresis are acceptable and often necessary to achieve decongestion. Persistent congestion is more harmful than modest creatinine elevation. 5

Medication adjustments for renal dysfunction:

• Review and potentially hold nephrotoxic agents: NSAIDs, COX-2 inhibitors (Class III, Level B) 1, 2
• Temporarily withhold spironolactone given acute renal dysfunction and risk of hyperkalemia (Class I, Level C) 3
• Continue ACE inhibitors/ARBs unless severe hemodynamic instability, recognizing that modest creatinine increases (up to 30% from baseline) are acceptable during optimization 3
• If creatinine increases >50% from baseline or exceeds 250 μmol/L (~2.8 mg/dL), consider dose reduction or temporary hold of RAAS inhibitors 3

Assess for reversible causes:

• Hypovolemia/hypotension (though unlikely given congestion)
• Urinary obstruction
• Concurrent nephrotoxic medications
• Infection

3. Elevated Troponin Management

The elevated troponin (46.60,44.70 ng/L) in the setting of acute decompensated heart failure likely represents type 2 myocardial injury from supply-demand mismatch rather than acute coronary syndrome, especially given:

• No acute ECG changes (ventricular paced rhythm unchanged)
• No evidence of pulmonary embolism on CT
• Context of severe heart failure with elevated filling pressures

However, acute coronary syndrome must be excluded as a precipitant (Class I, Level C). 6 Given the ventricular paced rhythm limiting ECG interpretation, consider cardiology consultation for risk stratification and potential need for coronary angiography if clinical suspicion exists.

4. Pleural Effusion Management

The large right pleural effusion contributes to dyspnea. Initial management is medical decongestion with diuretics. 1

• If persistent after adequate diuresis and causing significant respiratory compromise, consider therapeutic thoracentesis
• Oxygen therapy as needed to maintain SpO2 >90% (Class I, Level C) 6, 1

5. Continue Evidence-Based Heart Failure Therapies

Critical guideline recommendation: In acute decompensated chronic HFrEF, every attempt should be made to continue evidence-based disease-modifying therapies in the absence of hemodynamic instability or contraindications (Class I, Level C). 1, 2

This means:

• Continue beta-blockers unless cardiogenic shock or symptomatic hypotension/bradycardia
• Continue ACE inhibitors/ARBs (or ARNI if previously on it) unless severe hypotension or acute severe renal dysfunction
• Hold or reduce spironolactone temporarily given acute kidney injury and hyperkalemia risk
• Consider SGLT2 inhibitor if not already on one (beneficial even with eGFR 20-45) 7

Do NOT routinely discontinue these medications simply because the patient is hospitalized or has mild-moderate renal dysfunction.

6. Avoid Inotropes

Inotropic agents (dobutamine, milrinone, levosimendan) are NOT recommended unless the patient is symptomatically hypotensive or hypoperfused (Class III, Level A). 1, 2, 1, 2

This patient does not appear to have cardiogenic shock or symptomatic hypotension based on the presentation, so inotropes should be avoided due to safety concerns (increased arrhythmias, mortality).

Daily Monitoring Algorithm

Days 1-3:

• Assess volume status, vital signs, symptoms twice daily
• Daily labs: BUN, creatinine, electrolytes (Na, K)
• Daily weight
• Urine output monitoring
• Adjust diuretic dose based on response

Acceptable changes during diuresis:

• Creatinine increase up to 30% from baseline is acceptable if achieving decongestion 3
• BUN may rise disproportionately (prerenal pattern)
• Monitor for hypokalemia, hypomagnesemia requiring repletion

Red flags requiring intervention:

• Creatinine increase >50% or absolute value >2.8 mg/dL
• Severe hypokalemia (<3.0 mEq/L) or hyperkalemia (>5.5 mEq/L)
• Symptomatic hypotension
• Oliguria (<400 mL/day) without improvement in congestion

Transition to Discharge

Before transitioning to oral diuretics:

• Achieve clinical euvolemia (no orthopnea, clear lungs, minimal edema)
• Stable renal function for 24-48 hours
• Optimize oral GDMT dosing

At discharge:

• Ensure patient on maximally tolerated doses of beta-blocker, ACE-I/ARB (or ARNI), and consider SGLT2 inhibitor
• Restart spironolactone once renal function stabilizes and potassium normalized
• Arrange follow-up within 7 days (Class I, Level A) 1, 2
• Enroll in multidisciplinary heart failure management program (Class I, Level A) 1, 2

Special Considerations for This Patient

Age 84 with multiple comorbidities:

• Higher risk for adverse events from aggressive diuresis
• Careful attention to orthostatic hypotension
• Assess for frailty and functional status
• Consider palliative care consultation for goals of care discussion given advanced age, multiple comorbidities, and poor prognosis 8

Diabetes management:

• Avoid thiazolidinediones (glitazones) - Class III contraindication in heart failure 1, 2
• SGLT2 inhibitors preferred if not contraindicated
• Monitor glucose during acute illness

Anemia (Hgb 11.4 g/dL):

• Evaluate for reversible causes (iron, B12, folate deficiency, chronic blood loss) (Class I, Level C) 3
• Hemoglobin <110 g/L associated with worse outcomes in heart failure 3
• Consider transfusion only if symptomatic or Hgb <90 g/L 3